APA (7th ed.) Citation

MN, Q., J, C., P, R., BH, M., N, S., E, E., . . . PJ, T. (2025). Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host-Microbiome-Metabolomic Signatures. Journal of Crohn's & colitis, 19(2), . https://doi.org/10.1093/ecco-jcc/jjae189

Chicago Style (17th ed.) Citation

MN, Quraishi, et al. "Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host-Microbiome-Metabolomic Signatures." Journal of Crohn's & Colitis 19, no. 2 (2025). https://doi.org/10.1093/ecco-jcc/jjae189.

MLA (9th ed.) Citation

MN, Quraishi, et al. "Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host-Microbiome-Metabolomic Signatures." Journal of Crohn's & Colitis, vol. 19, no. 2, 2025, https://doi.org/10.1093/ecco-jcc/jjae189.